Published in Hepatitis Weekly, August 16th, 2004
Participants in this trial will have previously failed to respond to existing drugs for HCV and will receive one of several doses of IDN-6556, or placebo, given orally as a monotherapy for 3 months. This study will be conducted at 15 sites in the U.S. and is expected to enroll up to 200 patients.
"The initiation of this...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly